RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2012 /PRNewswire/ -- Grifols, a global healthcare company that produces medicines derived from human plasma, announced today it has a robust inventory of HyperRAB® S/D (rabies immune globulin [human]) to overcome U.S. supply constraints caused by an increase in rabies exposures during 2012. HyperRAB® S/D provides immediate immune protection to patients who are exposed to rabies but have not yet been vaccinated against the deadly virus.
The Centers for Disease Control and Prevention (CDC) confirmed in a September 19 announcement that Grifols' HyperRAB® S/D is the only immune globulin available in sufficient quantities to meet the market demand for rabies post-exposure prophylaxis – the recommended protocol to prevent rabies infection following exposure to the virus. Post-exposure prophylaxis consists of treatment with rabies immune globulin to provide rapid, temporary immunity against the virus followed by a series of rabies vaccines to generate permanent immunity.
According to the CDC, rabies infections among animals have increased in the past year as a result of a warm summer and a mild 2011 winter, with higher reported incidences of rabies among raccoons, skunks, foxes, beavers, and bats and an earlier start to the bat season.No human cases of rabies infection have been reported in the U.S. in 2012, but the number of human exposures to rabid animals appears higher this year. On a typical summer day, up to 100 cases of potential contacts with a rabid animal are reported across the nation. There were six cases of human rabies infections reported in 2011 – exceeding the typical annual numbers of only one or two. Grifols is committed to maintaining its supply of HyperRAB® S/D to meet the needs of patients who are potentially exposed to rabies. CDC guidelines recommend administering rabies immune globulin in conjunction with a patient's first rabies vaccination to ensure immediate protection against the rabies virus until the vaccine can mount a permanent defense.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV